Capecitabine Market Report

Global Capecitabine Market Size

The Global Capecitabine Market was valued at USD 496.81 billion in 2025, is estimated to reach USD 527.62 billion in 2026, and is projected to reach USD 853.72 billion by 2034, growing at a CAGR of 6.2% from 2026 to 2034.

Capecitabine is the drug commonly known as Xeloda, which is used therapeutically to treat various cancers. This drug works by inhibiting cell reproduction and repairing DNA, which stops cancer growth. Capecitabine drug is used in the chemotherapy of breast cancer, colorectal cancer, bowel cancer, and other cancer conditions. This drug is primarily recommended in combination with other drugs or given in single doses. The demand for capecitabine in the healthcare sector in cancer treatment is expected to drive the market in the forecast period. Capecitabine is a chemotherapy drug that works by reducing or preventing the progression of cancer cells. According to the American Cancer Society report, in 2017, there were predicted 135,431 new cases and 50,260 deaths from colon and rectal cancer in the US.

MARKET DRIVERS

The increasing demand for target drugs to decrease possible side effects without affecting healthy cells is likely to accelerate the application of the global capecitabine market.

The growing encumbrance for patients detected with cancer and tumors is to stimulate the market. According to the World Health Organization report, cancer is one of the leading causes of death worldwide, and it is estimated that about 9.6 million deaths in 2018. Besides, around 628,000 women have died from breast cancer, which accounts for about 15% of all cancer deaths in women worldwide. Also, a sharp increase in health spending and continued R&D activities in cancer treatment should offer new market opportunities.

The rising prevalence of various cancers is increasing the demand for cancer-treating drugs, which is driving the growth of the global capecitabine market.

According to the American Cancer Society, around 1.9 million new cancer cases are expected to be diagnosed in the U.S. by 2023, and approximately 609,820 cancer-related fatalities are expected. The rising number of cancer cases is driving the market growth. According to a World Health Organization report, cancer is the primary cause of mortality across the world, and an estimated 15% of women have breast cancer, which is boosting the market growth. The antimetabolite activity of capecitabine, which works by inhibiting DNA synthesis, is increasing the adoption of capecitabine in the healthcare system, enhancing the market value for capecitabine. The increasing demand for oral drugs among patients compared to intravenous injections is enhancing the capecitabine market worldwide.

The rising healthcare expenditure worldwide and innovative advancements in the healthcare system are accelerating the market growth for capecitabine.

Increasing government initiatives and collaborations with private organizations to increase cancer awareness among people and reduce cancer deaths are expected to increase market growth. North America stood as a global hub for cancer research due to rising research centers and academic institutions. The increasing number of pharmaceutical companies worldwide is enhancing the capecitabine market growth. Additionally, rising awareness programs from administrations and private administrations such as Cancer Care, Cancer Research UK, and Cancer Suraksha Scheme drive growth in the capecitabine market during the period.

There are increasing investments by the government in research and development activities to develop innovative drug forms to reduce cancer deaths. The key pharmaceutical companies are collaborating with the market players and other research organizations to develop drugs and innovative procedures for cancer treatment. The growing awareness programs by the government and private health organizations are educating the people regarding the treatment procedures, which is expected to provide opportunities for the capecitabine market growth. The healthcare system was seriously focused on cancer research, where some research centers were specially built for cancer. The rising reimbursement policies for cancer chemotherapy treatment by the healthcare system are augmenting the market growth.

MARKET RESTRAINTS

The major restraining factor for the capecitabine market growth is the side effects associated with using the capecitabine drug.

The side effects commonly observed in people using capecitabine are fatigue, loss of appetite, diarrhea, and mouth ulcers. Some occasional adverse effects are also observed in people, as they may vary from person to person depending on their body condition. The contraindications related to the drug such as lactose intolerance, pregnancy and breastfeeding fer, utility loss, and others. These cases of contraindications are limiting the capecitabine market revenue. The increasing cost of chemotherapy treatments, which cannot be affordable for patients from low economic backgrounds, is hindering capecitabine's market growth. The high cost of the capecitabine drug is limiting the market growth. The API of capecitabine includes multiple steps that contribute to challenges in the manufacturing process. The cost of manufacturing the API of capecitabine is high, increasing the final product's overall cost. Each step involves focused monitoring of reaction conditions, and specialized equipment and reagents are used. The requirement for experienced people in the synthesis of capecitabine increases production costs. All these factors are challenging for the market expansion of capecitabine. The stringent regulations regarding the safety and efficacy of the capecitabine drug by the regulatory bodies and government are impeding the market expansion.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Application Insights

The breast cancer segment dominated with the most significant share in the global capecitabine market in 2023 and is expected to have the dominant share in the forecast period due to the rising prescription of capecitabine drug for metastatic breast cancer treatment. Many research studies have shown the efficacy of capecitabine in breast cancer. The increasing number of breast cancers among women across the world is driving the segmental growth. According to WHO, at the end of 2020, around 7.8 million women were diagnosed with breast cancer, making it a more prevalent cancer. The government approvals for the capecitabine prodrug, which is highly effective for the treatment of metastatic breast cancer with a combination of other effective drugs.The colon and rectal cancer segments have gained traction in the market revenue recently due to effective treatment by capecitabine in these cancers. Medical professionals are prescribing capecitabine in combination with chemotherapy sessions for these cancers. The colon and rectal cancers are expected to grow steadily over the forecast period with a significant CAGR in the capecitabine market.

By Drug Formulation Insights

The tablets segment held the largest share in the global capecitabine market in 2023. The drug is mainly taken as oral tablets as they are taken twice a day for specific cycles after the meal. The drug was given in two periods where these were balanced with the different strengths of the tablets, making the correct dosage at the end of the day. The tablet formulation is highly preferred because of the higher shelf-life compared to the capsules. Capsules can be easily tampered with and are highly prone to microbial contamination. The tablets can easily accommodate the higher doses of API compared to capsules, which enhances the capecitabine market growth in the tablet drug formulation segment. Capsules tend to disintegrate unevenly compared to tablets in a few cases.

REGIONAL ANALYSIS

The North American region dominated the global capecitabine market with the most significant share in 2023 and is expected to dominate in the forecast period. The dominance in the region is due to the rising prevalence of cancer in developed countries like the U.S. and Canada. The growing adoption of urbanization is leading people to physical inactivity, obesity, stress, and sedentary lifestyles, which are prone to the occurrence of cancer. Various studies show that the cancer rate is high in North American countries, where an estimated 693,000 cancer deaths occurred in past years, with new diagnoses of 7.6 million people in 2020. North American region has the highest incidence of colorectal cancer worldwide. The advanced healthcare system in the North American region is boosting the market growth of capecitabine. The pharmaceuticals network is most prominent in the US and Canada, placing the North American region on top for market expansion. The North American region holds the key market players of domestic and international pharmaceutical companies, making it prominent in the capecitabine market share. North America is a global cancer research hub with top academic institutions and research centers.

Europe held the second position in the capecitabine market due to its advanced healthcare infrastructure. The European region held the top position, following the North American region, due to government and market player investments in R&D activities.

Asia Pacific held the third position in the market revenue of capecitabine due to increasing government initiatives for reducing cancer deaths by creating awareness among the people. The rising pharmaceutical companies and increasing breast cancer among the people in the region are enhancing the market value for capecitabine drugs in cancer treatment.

COMPETITIVE ANALYSIS

KEY MARKET PLAYERS

Some of the promising companies dominating the global capecitabine market profiled in this report are

• Novartis AG
• Sensus Healthcare
• RXi Pharmaceuticals, Inc.
• Sonoma Pharmaceuticals, Inc.
• Perrigo Company plc
• Bristol-Myers Squibb Company
• Pacific World Corporation
• Valeant Pharmaceuticals International, Inc.
• Revitol Corporation
• Avita Medical Limited.

RECENT HAPPENINGS IN THIS MARKET

• In December 2025, Shilpa Medicare announced the launch of a Capecitabine dispersible tablet, which dissolves in 90 seconds for treating colorectal and metastatic breast cancer. Launching this product helps the company develop its portfolio by enhancing market revenue.

• In February 2025, Dr Reddy's Laboratories launched Capecitabine tablets, a USP in the US market, the generic Xeloda (Capecitabine) tablets. These tablets were approved by the US Food and Drug Administration, which enhanced the company's business revenue and product portfolio.

• In April 2025, Armas Pharmaceuticals, Inc. was delighted to publicize the launch of its second and third generic products, Imatinib and Capecitabine, for the US market. These products will be the first reliable oral oncology products for Weapons. Capecitabine will be available in 150mg and 500mg doses and Imatinib will be available in 100mg and 400mg doses.
• In July 2025, Hikma Pharmaceuticals, headquartered at Hikma Pharmaceuticals launched 150mg and 500mg tablets of Capecitabine, the generic equivalent of Xeloda, through its affiliate West-Ward Pharmaceuticals. West-Ward Capecitabine tablets are indicated for adjuvant therapy in patients with colon cancer C as monotherapy for metastatic colorectal cancer.
• In August 2025, Mylan Inc. (Nasdaq: MYL) announced the release of Capecitabine Tablets USP, 150mg and 500mg, the generic version of Genentech Xeloda® tablets. Mylan received final approval from the United States Food and Drug Administration (FDA) for its Short Drug Application (ANDA) for this product.

MARKET SEGMENTATION

This research report on the global capecitabine market has been segmented and sub-segmented into the following categories.

By Application

• Colon Cancer
• Rectal Cancer
• Breast Cancer
• Gastric Cancer
• Others

By Drug Formulation

• Tablets
• Capsules

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa